| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Eriocalyxin B targets multiple cellular pathways involved in inflammation, proliferation, and cell death. It is a potent NF-κB inhibitor and exerts anti-inflammatory effects through selective modulation of pathogenic Th1 and Th17 cells. The compound also targets apoptosis, autophagy, reactive oxygen species, CDK, PPAR, FABP, Akt, and mTOR pathways. Eriocalyxin B induces cell apoptosis through inhibition of the Akt/mTOR/p70S6K signaling pathway.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, Eriocalyxin B inhibits NF-κB activity. The compound's anti-inflammatory effects are mediated through the modulation of Th1 and Th17 cell signaling. Eriocalyxin B (0-3.5 μM; 7 days) inhibits adipogenesis in 3T3-L1 preadipocytes with an IC50 of 2.745 μM and inhibits the expression of C/EBPα, C/EBPβ, PPARγ, and FABP4.
|
| ln Vivo |
In cell-based assays, Eriocalyxin B has shown cytotoxic activity against various tumor cell lines including A-549, MCF-7, SMMC-7721, SW-480, and HL-60 with IC50 values ranging from 0.3-3.1 μM. Eriocalyxin B (1.25-3.5 μM; 16-48 h) induces G2/M phase arrest in differentiated 3T3-L1 cells. Eriocalyxin B (0.35-2.25 μM; 24-72 h) inhibits cell viability, increases intracellular ROS generation, and induces apoptosis and autophagy in MCF-7 and MDA-MB-231 cells.
|
| Enzyme Assay |
The cell-free assay for Eriocalyxin B involves measuring its effects on purified enzymes and signaling proteins. The compound's inhibition of NF-κB can be assessed using kinase assays with purified IKK and other components. The compound's anti-adipogenic activity can be evaluated using cell-free assays measuring the expression of adipogenic transcription factors. The compound's binding to target proteins can be studied using surface plasmon resonance or isothermal titration calorimetry.
|
| Cell Assay |
Cell-based assays for Eriocalyxin B involve culturing cancer cell lines and treating them with the compound at concentrations ranging from 0.1 to 10 μM. Cells are incubated for 24-72 hours, and cell viability is assessed using MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V staining, caspase activity assays, and PARP cleavage. Autophagy is assessed by measuring LC3-II and p62 levels. Cell cycle analysis is performed by flow cytometry. The compound's effects on NF-κB, Akt/mTOR, and other signaling pathways are assessed by Western blotting.
|
| Animal Protocol |
In animal models, Eriocalyxin B has been evaluated for its anti-inflammatory and anti-tumor activities. Typical studies involve administration of the compound to mice via intraperitoneal or oral routes. Inflammatory disease models are used to assess the compound's ability to modulate Th1 and Th17 cells. Tumor-bearing mice are used to assess anti-tumor efficacy. Tissues are collected for analysis of inflammatory markers, apoptosis, and signaling pathway modulation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Eriocalyxin B have not been extensively reported. As a diterpenoid with a molecular weight of 344.40 g/mol, it would be expected to have moderate oral bioavailability and tissue penetration. The compound is soluble in DMSO: 20 mg/mL (58.07 mM). It is typically stored at 4°C, protected from light; in solvent at -80°C for 6 months or at -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Eriocalyxin B is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this natural product. As a compound with diverse biological activities, it may have effects on multiple cellular processes. The compound is typically stored at 4°C, protected from light. Standard toxicity studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Reports indicate that Eriocalyxin B has been found in Isodon eriocalyx, and relevant data is available for reference.
Eriocalyxin B is a research-grade natural product supplied for cancer and inflammation research. It is not an approved pharmaceutical and has no clinical trial history. The compound is a natural diterpenoid from Isodon eriocalyx. It has anticancer and anti-inflammatory activities and induces cell apoptosis and autophagy. This product is intended for research use only. |
| Molecular Formula |
C20H24O5
|
|---|---|
| Molecular Weight |
344.40
|
| Exact Mass |
344.162
|
| CAS # |
84745-95-9
|
| PubChem CID |
16202215
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
551.1±50.0 °C at 760 mmHg
|
| Flash Point |
198.9±23.6 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.627
|
| LogP |
2.16
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
25
|
| Complexity |
766
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC1(C=CC(=O)[C@]23[C@@H]1[C@@H]([C@]([C@]45[C@H]2CC[C@H](C4)C(=C)C5=O)(OC3)O)O)C
|
| InChi Key |
RTIKCEKESDRWAE-UJVKWQRCSA-N
|
| InChi Code |
InChI=1S/C20H24O5/c1-10-11-4-5-12-18-9-25-20(24,19(12,8-11)15(10)22)16(23)14(18)17(2,3)7-6-13(18)21/h6-7,11-12,14,16,23-24H,1,4-5,8-9H2,2-3H3/t11-,12+,14-,16+,18-,19+,20-/m1/s1
|
| Chemical Name |
(1S,2S,5R,8S,9S,10S,11R)-9,10-dihydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadec-13-ene-7,15-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9036 mL | 14.5180 mL | 29.0360 mL | |
| 5 mM | 0.5807 mL | 2.9036 mL | 5.8072 mL | |
| 10 mM | 0.2904 mL | 1.4518 mL | 2.9036 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
